Tasly Pharmaceutical

Tasly Pharmaceuticals Inc. is a pioneering private company, founded in 2006 and headquartered in Rockville, Maryland, that focuses on botanical drug development. Its lead asset, T89 (Dantonic®), is a breakthrough compound for chronic stable angina that has completed a global FDA Phase III trial, positioning it as a potential first-in-class botanical prescription drug. The company leverages a model of rigorous clinical validation and quality control to advance plant-based therapeutics, primarily targeting cardiovascular disease, and aims to establish a new category of synergistic, long-term treatment options alongside conventional medicine.

Integrated botanical drug development platform focusing on standardized, multi-component plant extracts validated through modern analytical chemistry, pharmacology, and clinical trials. It emphasizes the synergistic action of complex botanical mixtures.

Tasly's direct competitors are few, as the FDA-approved botanical drug space is extremely limited. However, T89 competes indirectly with all approved anti-anginal drugs (nitrates, beta-blockers, etc.) and dietary supplements for heart health. Its unique position is as a potential prescription-grade, clinically validated botanical therapeutic.